Literature DB >> 8813264

Gastric juice protects against the development of esophageal adenocarcinoma in the rat.

A P Ireland1, J H Peters, T C Smyrk, T R DeMeester, G W Clark, S S Mirvish, T E Adrian.   

Abstract

OBJECTIVE: The authors investigate the effects of gastric juice on tumorigenesis in a rat model of esophageal adenocarcinoma. SUMMARY BACKGROUND DATA: In rats treated with the carcinogen methyl-n-amyl nitrosamine, squamous cancer of the esophagus develops in a time- and dose-dependent manner. When methyl-n-amyl nitrosamine treatment is preceded by an operation to induce reflux of duodenal and gastric juice into the esophagus, there is an increased yield of esophageal tumors, many of which are adenocarcinomas. When only gastric juice refluxes into the esophagus, the tumor yield is less and adenocarcinomas are not found.
METHODS: Two hundred seventy 8-week old Sprague-Dawley rats were studied. Twenty unoperated rats served as controls. The remaining rats underwent the following operations: esophagoduodenostomy with gastric and vagal preservation to induce duodenogastroesophageal reflux (n = 48); esophagoduodenostomy with antrectomy and Billroth 1 reconstruction to produce reflux of duodenogastric juice with the exclusion of the antrum (n = 53); esophagoduodenostomy with proximal gastrectomy to induce hypergastrinemia and reflux of duodenogastric juice with exclusion of the body and forestomach (n = 51); esophagoduodenostomy plus total gastrectomy to produce reflux of duodenal juice alone (n = 50); and esophagoduodenostomy with vagal and gastric preservation but with division of the duodenum just beyond the pylorus and reimplantation into the jejunum, 13 cm distal to the esophagoduodenostomy. This produced reflux of duodenal juice with gastric juice diverted downstream, (n = 48). At 10 weeks of age, all rats were given 4 weekly doses of carcinogen (methyl-n-amyl nitrosamine, 25 mg/kg intraperitoneally), and survivors were killed at 36 weeks of age.
RESULTS: The prevalence rate of esophageal adenocarcinoma was 30% in rats with duodenogastroesophageal reflux and 87% in rats with reflux of duodenal juice alone. Fifty-six percent of rats with reflux of duodenogastric juice with exclusion of the antrum and 72% of rats with reflux of duodenogastric juice with the exclusion of the body and forestomach developed adenocarcinoma, showing a progression increase in the prevalence of adenocarcinoma as less gastric juice was permitted to reflux with duodenal juice into the esophagus.
CONCLUSION: In this rat model, the presence of gastric juice in refluxed duodenal juice against the development of esophageal adenocarcinoma. The protective effect appears to be due to acid secretion from the stomach. Continuous profound acid suppression therapy may be detrimental by encouraging esophageal metaplasia and tumorigenesis in patients with duodenogastroesophageal reflux.

Entities:  

Mesh:

Year:  1996        PMID: 8813264      PMCID: PMC1235382          DOI: 10.1097/00000658-199609000-00012

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  29 in total

1.  Relative importance of biliary and pancreatic secretions in the genesis of esophagitis in rats.

Authors:  R LAMBERT
Journal:  Am J Dig Dis       Date:  1962-11

2.  Oesophageal lesions following total gastrectomy in rats. I. Development and nature.

Authors:  N HELSINGEN
Journal:  Acta Chir Scand       Date:  1960-01-30

3.  Esophagitis produced by reflux of duodenal contents in rats.

Authors:  M LEVRAT; R LAMBERT; G KIRSHBAUM
Journal:  Am J Dig Dis       Date:  1962-06

4.  Duodenoesophageal reflux and the development of esophageal adenocarcinoma in rats.

Authors:  S E Attwood; T C Smyrk; T R DeMeester; S S Mirvish; H J Stein; R A Hinder
Journal:  Surgery       Date:  1992-05       Impact factor: 3.982

Review 5.  Barrett's esophagus.

Authors:  S J Spechler; R K Goyal
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

6.  Alkaline gastroesophageal reflux: assessment by ambulatory esophageal aspiration and pH monitoring.

Authors:  H J Stein; H Feussner; W Kauer; T R DeMeester; J R Siewert
Journal:  Am J Surg       Date:  1994-01       Impact factor: 2.565

7.  Continuing climb in rates of esophageal adenocarcinoma: an update.

Authors:  W J Blot; S S Devesa; J F Fraumeni
Journal:  JAMA       Date:  1993-09-15       Impact factor: 56.272

8.  Barrett's esophagus: development of dysplasia and adenocarcinoma.

Authors:  W Hameeteman; G N Tytgat; H J Houthoff; J G van den Tweel
Journal:  Gastroenterology       Date:  1989-05       Impact factor: 22.682

9.  Regnerative of cardiac type mucosa and acquisition of Barrett mucosa after esophagogastrostomy.

Authors:  S R Hamilton; J H Yardley
Journal:  Gastroenterology       Date:  1977-04       Impact factor: 22.682

10.  Does duodenal juice reflux into the esophagus of patients with complicated GERD? Evaluation of a fiberoptic sensor for bilirubin.

Authors:  W K Kauer; P Burdiles; A P Ireland; G W Clark; J H Peters; C G Bremner; T R DeMeester
Journal:  Am J Surg       Date:  1995-01       Impact factor: 2.565

View more
  27 in total

Review 1.  Medical treatment of Barrett's esophagus.

Authors:  S J Spechler
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

2.  Impact of the biliary diversion procedure on carcinogenesis in Barrett's esophagus surgically induced by duodenoesophageal reflux in rats.

Authors:  Koji Nishijima; Koichi Miwa; Tomoharu Miyashita; Shinichi Kinami; Itasu Ninomiya; Sachio Fushida; Takashi Fujimura; Takanori Hattori
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

3.  Barrett's esophagus and animal models.

Authors:  Ryan A Macke; Katie S Nason; Ken-ichi Mukaisho; Takanori Hattori; Takashi Fujimura; Shozo Sasaki; Katsunobu Oyama; Tomoharu Miyashita; Tetsuo Ohta; Koichi Miwa; Michael K Gibson; Ali Zaidi; Usha Malhotra; Ajlan Atasoy; Tyler Foxwell; Blair Jobe
Journal:  Ann N Y Acad Sci       Date:  2011-09       Impact factor: 5.691

4.  Emerging concepts of bile reflux in the constellation of gastroesophageal reflux disease.

Authors:  Werner K H Kauer; Hubert J Stein
Journal:  J Gastrointest Surg       Date:  2009-09-12       Impact factor: 3.452

5.  Metaplastic columnar mucosa in the cervical esophagus after esophagectomy.

Authors:  Stefan Oberg; Jan Johansson; Jörgen Wenner; Bruno Walther
Journal:  Ann Surg       Date:  2002-03       Impact factor: 12.969

6.  Esophageal malignancy: a growing concern.

Authors:  Jianyuan Chai; M Mazen Jamal
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

7.  Validation of a rodent model of Barrett's esophagus using quantitative gene expression profiling.

Authors:  Daniel S Oh; Steven R DeMeester; Christy M Dunst; Ryutaro Mori; Bethany J Lehman; Hidekazu Kuramochi; Kathleen Danenberg; Peter Danenberg; Jeffrey A Hagen; Parakrama Chandrasoma; Tom R DeMeester
Journal:  Surg Endosc       Date:  2008-09-24       Impact factor: 4.584

Review 8.  Contribution of immunomodulators to gastroesophageal reflux disease and its complications: stromal cells, interleukin 4, and adiponectin.

Authors:  Jing Li; Xiaoxin Luke Chen; Anisa Shaker; Tadayuki Oshima; Jing Shan; Hiroto Miwa; Cheng Feng; Jun Zhang
Journal:  Ann N Y Acad Sci       Date:  2016-07-21       Impact factor: 5.691

Review 9.  Experimental evidence for mutagenic potential of duodenogastric juice on Barrett's esophagus.

Authors:  Joerg Theisen; Jeffrey H Peters; Hubert J Stein
Journal:  World J Surg       Date:  2003-07-17       Impact factor: 3.352

10.  Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma.

Authors:  Jie Hong; Jose Behar; Jack Wands; Murray Resnick; Li Juan Wang; Ronald A DeLellis; David Lambeth; Rhonda F Souza; Stuart J Spechler; Weibiao Cao
Journal:  Gut       Date:  2009-11-18       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.